232 related articles for article (PubMed ID: 32019112)
21. Suppression of Myc oncogenic activity by nucleostemin haploinsufficiency.
Zwolinska AK; Heagle Whiting A; Beekman C; Sedivy JM; Marine JC
Oncogene; 2012 Jul; 31(28):3311-21. PubMed ID: 22081066
[TBL] [Abstract][Full Text] [Related]
22. Endogenous Bcl-xL is essential for Myc-driven lymphomagenesis in mice.
Kelly PN; Grabow S; Delbridge AR; Strasser A; Adams JM
Blood; 2011 Dec; 118(24):6380-6. PubMed ID: 21998213
[TBL] [Abstract][Full Text] [Related]
23. Genomic characterisation of Eμ-Myc mouse lymphomas identifies Bcor as a Myc co-operative tumour-suppressor gene.
Lefebure M; Tothill RW; Kruse E; Hawkins ED; Shortt J; Matthews GM; Gregory GP; Martin BP; Kelly MJ; Todorovski I; Doyle MA; Lupat R; Li J; Schroeder J; Wall M; Craig S; Poortinga G; Cameron D; Bywater M; Kats L; Gearhart MD; Bardwell VJ; Dickins RA; Hannan RD; Papenfuss AT; Johnstone RW
Nat Commun; 2017 Mar; 8():14581. PubMed ID: 28262675
[TBL] [Abstract][Full Text] [Related]
24. Msh2-dependent DNA repair mitigates a unique susceptibility of B cell progenitors to c-Myc-induced lymphomas.
Nepal RM; Tong L; Kolaj B; Edelmann W; Martin A
Proc Natl Acad Sci U S A; 2009 Nov; 106(44):18698-703. PubMed ID: 19837692
[TBL] [Abstract][Full Text] [Related]
25. p53-dependent senescence delays Emu-myc-induced B-cell lymphomagenesis.
Post SM; Quintás-Cardama A; Terzian T; Smith C; Eischen CM; Lozano G
Oncogene; 2010 Mar; 29(9):1260-9. PubMed ID: 19935700
[TBL] [Abstract][Full Text] [Related]
26. MYC selects against reduced BCL2A1/A1 protein expression during B cell lymphomagenesis.
Sochalska M; Schuler F; Weiss JG; Prchal-Murphy M; Sexl V; Villunger A
Oncogene; 2017 Apr; 36(15):2066-2073. PubMed ID: 27694901
[TBL] [Abstract][Full Text] [Related]
27. AID and RAG1 do not contribute to lymphomagenesis in Emu c-myc transgenic mice.
Nepal RM; Zaheen A; Basit W; Li L; Berger SA; Martin A
Oncogene; 2008 Aug; 27(34):4752-6. PubMed ID: 18408759
[TBL] [Abstract][Full Text] [Related]
28. Elevated Mdm2 expression induces chromosomal instability and confers a survival and growth advantage to B cells.
Wang P; Lushnikova T; Odvody J; Greiner TC; Jones SN; Eischen CM
Oncogene; 2008 Mar; 27(11):1590-8. PubMed ID: 17828300
[TBL] [Abstract][Full Text] [Related]
29. Endogenous bcl-2 is not required for the development of Emu-myc-induced B-cell lymphoma.
Kelly PN; Puthalakath H; Adams JM; Strasser A
Blood; 2007 Jun; 109(11):4907-13. PubMed ID: 17317859
[TBL] [Abstract][Full Text] [Related]
30. Loss of a Single Mcl-1 Allele Inhibits MYC-Driven Lymphomagenesis by Sensitizing Pro-B Cells to Apoptosis.
Grabow S; Delbridge AR; Aubrey BJ; Vandenberg CJ; Strasser A
Cell Rep; 2016 Mar; 14(10):2337-47. PubMed ID: 26947081
[TBL] [Abstract][Full Text] [Related]
31. Eμ-TCL1xMyc: A Novel Mouse Model for Concurrent CLL and B-Cell Lymphoma.
Lucas F; Rogers KA; Harrington BK; Pan A; Yu L; Breitbach J; Bundschuh R; Goettl VM; Hing ZA; Kanga P; Mantel R; Sampath D; Smith LL; Wasmuth R; White DK; Yan P; Byrd JC; Lapalombella R; Woyach JA
Clin Cancer Res; 2019 Oct; 25(20):6260-6273. PubMed ID: 31296529
[TBL] [Abstract][Full Text] [Related]
32. MIF loss impairs Myc-induced lymphomagenesis.
Talos F; Mena P; Fingerle-Rowson G; Moll U; Petrenko O
Cell Death Differ; 2005 Oct; 12(10):1319-28. PubMed ID: 15947793
[TBL] [Abstract][Full Text] [Related]
33. AKT signalling is required for ribosomal RNA synthesis and progression of Eμ-Myc B-cell lymphoma in vivo.
Devlin JR; Hannan KM; Ng PY; Bywater MJ; Shortt J; Cullinane C; McArthur GA; Johnstone RW; Hannan RD; Pearson RB
FEBS J; 2013 Nov; 280(21):5307-16. PubMed ID: 23331925
[TBL] [Abstract][Full Text] [Related]
34. Oncogenic c-Myc-induced lymphomagenesis is inhibited non-redundantly by the p19Arf-Mdm2-p53 and RP-Mdm2-p53 pathways.
Meng X; Carlson NR; Dong J; Zhang Y
Oncogene; 2015 Nov; 34(46):5709-17. PubMed ID: 25823025
[TBL] [Abstract][Full Text] [Related]
35. MYC-driven malignant transformation of mature murine B cells requires inhibition of both intrinsic apoptosis and p53 activity.
Högstrand K; Grandien A
Eur J Immunol; 2019 Mar; 49(3):375-385. PubMed ID: 30281155
[TBL] [Abstract][Full Text] [Related]
36. A new model of LMP1-MYC interaction in B cell lymphoma.
Ontiveros EP; Halwani A; Stunz LL; Kamberos N; Olivier AK; Janz S; Bishop GA
Leuk Lymphoma; 2014 Dec; 55(12):2917-23. PubMed ID: 24605938
[TBL] [Abstract][Full Text] [Related]
37. Id2 is dispensable for myc-induced lymphomagenesis.
Nilsson JA; Nilsson LM; Keller U; Yokota Y; Boyd K; Cleveland JL
Cancer Res; 2004 Oct; 64(20):7296-301. PubMed ID: 15492249
[TBL] [Abstract][Full Text] [Related]
38. IgH enhancer deregulated expression of L-myc: abnormal T lymphocyte development and T cell lymphomagenesis.
Möröy T; Fisher P; Guidos C; Ma A; Zimmerman K; Tesfaye A; DePinho R; Weissman I; Alt FW
EMBO J; 1990 Nov; 9(11):3659-66. PubMed ID: 2120050
[TBL] [Abstract][Full Text] [Related]
39. Ink4c is dispensable for tumor suppression in Myc-induced B-cell lymphomagenesis.
Nilsson LM; Keller UB; Yang C; Nilsson JA; Cleveland JL; Roussel MF
Oncogene; 2007 May; 26(20):2833-9. PubMed ID: 17099725
[TBL] [Abstract][Full Text] [Related]
40. Mnt modulates Myc-driven lymphomagenesis.
Campbell KJ; Vandenberg CJ; Anstee NS; Hurlin PJ; Cory S
Cell Death Differ; 2017 Dec; 24(12):2117-2126. PubMed ID: 28800127
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
